Sign in
Back
Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al
Journal article   Open access  Peer reviewed

Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al

S. J. Kim and W. S. Kim
Annals of oncology, Vol.27(11), pp.2133-2134
01/11/2016
DOI: https://doi.org/10.1093/annonc/mdw296
PMID: 27502713

Abstract

Life Sciences & Biomedicine Oncology Science & Technology
This is our reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.
url
https://doi.org/10.1093/annonc/mdw296View
Published (Version of record) Open

Metrics

1 Record Views

Details